Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

166.04USD
23 Mar 2017
Change (% chg)

$-1.41 (-0.84%)
Prev Close
$167.45
Open
$167.48
Day's High
$168.02
Day's Low
$165.57
Volume
4,430,554
Avg. Vol
3,924,313
52-wk High
$184.21
52-wk Low
$133.64

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $123,319.00
Shares Outstanding(Mil.): 736.45
Dividend: 1.15
Yield (%): 2.75

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.32 48.09 29.63
EPS (TTM): 10.26 -- --
ROI: 11.95 -2.54 13.01
ROE: 26.65 5.17 14.16

BRIEF-European Commission approves Amgevita for treatment of certain inflammatory diseases

* European Commission approves Amgevita™ (biosimilar adalimumab) for the treatment of certain inflammatory diseases

4:47pm EDT

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

UPDATE 1-Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON, March 21 Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON, March 21 Sanofi SA and Regeneron Pharmaceuticals Inc filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

Wall St. flat as banks, Amgen weigh; Adobe rallies

NEW YORK U.S. stocks dipped on Friday as bank shares fell alongside Treasury yields while Adobe helped buoy the S&P tech sector and the Nasdaq Composite. | Video

Mar 17 2017

US STOCKS-Wall St flat as banks, Amgen weigh; Adobe rallies

* Dow down 0.1 pct, S&P 500 down 0.13 pct, Nasdaq flat (Updates to market close, changes comment, byline)

Mar 17 2017

Express Scripts says Amgen data opens door to patients

NEW YORK Express Scripts Holding Co Chief Medical Officer Dr. Steve Miller said on Friday that the data on heart drug Repatha from Amgen Inc was incrementally better and would change patient access to the drug.

Mar 17 2017

Express Scripts says Amgen data opens door to patients

NEW YORK, March 17 Express Scripts Holding Co Chief Medical Officer Dr. Steve Miller said on Friday that the data on heart drug Repatha from Amgen Inc was incrementally better and would change patient access to the drug.

Mar 17 2017

US STOCKS-Wall St little changed as healthcare stocks weigh

* Dow up 0.06 pct, S&P up 0.05 pct, Nasdaq down 0.03 pct (Updates to open)

Mar 17 2017

More From Around the Web

Earnings vs. Estimates